A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of valsartan and hydrochlorothiazide

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Hydrochlorothiazide; Valsartan

Criteria

Inclusion Criteria

• Patients with essential hypertension

• Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.

• Patients who are eligible and able to participate in the study

Exclusion Criteria

• Severe hypertension

• Uncontrolled diabetes type I and II

• History or evidence of a secondary form of hypertension

• History of Hypertensive encephalopathy or cerebrovascular accident.

Other protocol-defined exclusion criteria may apply.